Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
This study was conducted to investigate the potential for a pharmacokinetic drug-drug interaction in patients with mild-to-moderate hypertension in support of the co-administration of LCZ696 and sildenafil.
Age
18–65
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Male subjects with mild to moderate hypertension, either treated or not currently on treatment, between age 18 and 65 years of age, and otherwise in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening.
At screening: systolic blood pressure 120-140 mmHg on therapy, or 140-160 mmHg if untreated
At screening: diastolic blood pressure, 70-95 mmHg on therapy, or 90-100 mmHg if untreated
Baseline: BP ≥140/90;
You may not be if
Use of non-antihypertensive prescription drugs, herbal supplements, and/or over-the-counter (OTC) medication, dietary supplements (vitamins included) within two (2) weeks prior to initial dosing
Clareo Health | Evaluation of Drug-drug Interaction Between LCZ696 and Sildenafil in Subjects With Mild to Moderate Hypertension
